Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) continues to have a pipeline of drugs that might provide further validation for the company's platform, but recent updates were not a roaring success.

Shares in Recursion fell by 13.4% on 5 May, dropping from $5.49 at market open to $4.76 at close following the pipeline restructuring announcement. The terminated programmes include REC-2282, REC ...

Taking a closer look at the pipeline casualties, Recursion is deprioritizing clinical-stage programs REC-2282, REC-994 and REC-3964, which the company was developing in neurofibromatosis type 2 ...

Recursion will host a (L)earnings Call on May 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm BST from Recursion’s X (formerly Twitter), LinkedIn, and YouTube accounts giving analysts, investors ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were skyrocketing around 20% higher as of 11 a.m. ET on Friday. The big gain for the biotech stock came after the U.S. Food and Drug ...

13 September 2024 Creating an AI-first drug discovery engine Najat Khan — Chief R&D Officer and Chief Commercial Officer at Recursion — discusses the proposed merger of Recursion and Exscientia.

Recursion and iteration are two common ways to traverse and manipulate composite structures, such as trees, graphs, or nested lists. But how do you decide which one to use for a given problem?

After a tough year, Exscientia will merge into Recursion, creating one company that has 10 clinical readouts expected over the next 18 months.